AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21412168
Drug: Cisplatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (40 mg/m intravenous) weekly on day 2 + phenoxodiol (3 mg/kg) weekly on days 1 and 2
Trial: 21412168
Drug: Paclitaxel (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (80 mg/m IV) weekly on day 2 + phenoxodiol (3 mg/kg) weekly on days 1 and 2
Trial: 19638927
Drug: Conventional clamp
RxNorm normalized name: CLAMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional clamp crushing method (CC group)
Trial: 11916756
Drug: 7 mg
RxNorm normalized name: pectin 7 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 mg threonine x kg(‐1) x d(‐1)
Trial: 11916756
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg threonine x kg(‐1) x d(‐1)
Trial: 11916756
Drug: 46 mg
RxNorm normalized name: lufenuron 46 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 46 mg threonine x kg(‐1) x d(‐1)
Trial: 9802665
Drug: Professional physical
RxNorm normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Professional physical therapy
Trial: 33753
Drug: Alkaline artificial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkaline artificial tear preparation
Trial: 33753
Drug: Current artificial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current artificial tear preparations available in North America
Trial: 30445507
Drug: Learn to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Learn to Quit (LTQ) app combined with nicotine replacement therapy and technical coaching
Trial: 30445507
Drug: NCI QuitGuide
RxNorm normalized name: Belagenpumatucel-L (NCI H-520)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NCI QuitGuide (QG) app combined with nicotine replacement therapy and technical coaching
Trial: 10096452
Drug: Chlorphenylamine (CP),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorphenylamine (CP), administered daily for 7 days
Trial: 10096452
Drug: Flurbiprofen (FB),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (FB), administered daily for 7 days
Trial: 7755942
Drug: 375 mg
RxNorm normalized name: niacin 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg naproxen twice a day
Trial: 2129651
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg aminophylline i.v.
Trial: 2129651
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg doxofylline i.v.
Trial: 2129651
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg doxofylline i.v.
Trial: 28126304
Drug: 5-fluorouracil/mitomycin-C/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil/mitomycin-C/radiation therapy (Arm A)
Trial: 28126304
Drug: 5-fluorouracil/cisplatin/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil/cisplatin/radiation therapy (Arm B)
Trial: 17386123
Drug: Capecitabine and
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine and weekly paclitaxel
Trial: 16033307
Drug: Overall risk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall risk of repeat therapy due to any recurrent infection
Trial: 11981007
Drug: Ibandronate 2
RxNorm normalized name: ibandronate 2.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate 2 mg IV monthly for 12 to 24 months
Trial: 11981007
Drug: Ibandronate 2
RxNorm normalized name: ibandronate 2.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate 2 mg IV monthly
Trial: 7530984
Drug: Tumour-infiltrating lymphocyte
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumour-infiltrating lymphocyte (TIL) infusion
Trial: 27749225
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of NSAIDs
Trial: 18257344
Drug: Slowly-releasing medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slowly-releasing medication (intramuscular injection, made from Chinese herbs, administered at specific acupuncture points)
Trial: 18257344
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (Rythmol, oral administration, 150 mg thrice daily)
Trial: 17023280
Drug: 0.3% ropivacaine/fentanyl,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% ropivacaine/fentanyl, 3 microg/mL
Trial: 17023280
Drug: 0.25% bupivacaine/fentanyl,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine/fentanyl, 3 microg/mL
Trial: 14514745
Drug: Protocolized anemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocolized anemia management with subcutaneous rHuEpo and intravenous iron
Trial: 10810685
Drug: Patient-controlled continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled continuous infusion of lidocaine (2% solution, 2 cc/h continuous dose, 1 cc at 15-minute intervals for 72 hours)
Trial: 1666917
Drug: Oral CBD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral CBD (10 mg/kg/day = about 700 mg/day) for 6 weeks
Trial: 7105820
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg chlormezanone at night
Trial: 7105820
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg diazepam 3-times daily for 4 weeks
Trial: 27584142
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (monitoring, G3)
Trial: 26013912
Drug: Cocoa flavanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa flavanol (CF) intake (450 mg CF) bi-daily for 14 days
Trial: 26013912
Drug: Nutrient-matched, CF-free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrient-matched, CF-free control drink bi-daily for 14 days
Trial: 9388311
Drug: Electro-acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electro-acupuncture treatment
Trial: 17224808
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus patient choice of acupuncture, chiropractic, or massage therapy (choice)
Trial: 3207560
Drug: Felodipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (10 mg single dose) with indomethacin pretreatment (25 mg four times daily for 3 days)
Trial: 3207560
Drug: Indomethacin treatment
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin treatment alone
Trial: 2444797
Drug: Felodipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (10 mg single dose)
Trial: 30827852
Drug: Low-energy extracorporeal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy extracorporeal shockwave therapy (0.05-0.20mJ/mm2, frequency of 4Hz, 1000 to 2000 shocks, once per week for 4 weeks)
Trial: 24004232
Drug: Butorphanol (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol (0.4 mg/kg, SC)
Trial: 24004232
Drug: Methadone (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (0.6 mg/kg, SC)
Trial: 19397429
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of 0.25% bupivacaine infiltration
Trial: 1972861
Drug: xamoterol, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xamoterol, 200 mg twice a day
Trial: 93486
Drug: Individual speech
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual speech therapy
Trial: 31045830
Drug: Soshiho-tang (SSHT)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Soshiho-tang (SSHT) administered 3 times a day for 4 weeks
Trial: 31914034
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 3 times a day for 4 weeks
Trial: 22928803
Drug: Botulinum Toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum Toxin Type-A (BoNT-A) injection
Trial: 21342644
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy followed concurrent chemoradiotherapy (Paclitaxel liposme 135 mg/m²-175 mg/m², d1 and cisplatin 70 mg/m²-80 mg/m², d2, 3 weeks repeat)
Trial: 21342644
Drug: Sequential radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential radiotherapy (4-6 cycles of chemotherapy followed by one cycle of radiotherapy)
Trial: 21342644
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy followed concurrent chemoradiotherapy
Trial: 21342644
Drug: Sequential radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential radiotherapy
Trial: 19688338
Drug: Liraglutide 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 1.8 mg once daily (n = 230)
Trial: 19688338
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (n = 232)
Trial: 19039821
Drug: Modafinil (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (300 mg)
Trial: 3516092
Drug: tibalosine 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tibalosine 150 mg daily
Trial: 3516092
Drug: tibalosine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tibalosine plus atenolol 100 mg
Trial: 3516092
Drug: tibalosine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tibalosine plus chlorthalidone 50 mg
Trial: 31053348
Drug: Cefuroxime administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime administered before skin incision
Trial: 31053348
Drug: Cefuroxime administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime administered after cutting the umbilical cord
Trial: 25838311
Drug: Intravenous sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium nitrite (NaNO2) at 50 μg/kg/min
Trial: 25838311
Drug: Intravenous sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium nitrite (NaNO2) at 10 μg/kg/min
Trial: 23785676
Drug: Subcutaneous specific
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous specific immunotherapy in 57 allergic patients (70.3%)
Trial: 23785676
Drug: Intranasal glucocorticosteroids
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal glucocorticosteroids in 47 patients with rhinitis medicamentosa (37.9%)
Trial: 20979591
Drug: Tegaserod 6
RxNorm normalized name: tegaserod 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod 6 mg b.i.d
Trial: 15536601
Drug: No pharmacologic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pharmacologic treatment
Trial: 11559654
Drug: olsalazine 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olsalazine 2.0 g daily for 52 weeks
Trial: 9211442
Drug: Haloperidol treatment
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol treatment for 6 weeks
Trial: 2527533
Drug: Cilazapril (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril (0.5 to 5 mg dose range)
Trial: 21344327
Drug: Systemic antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotics (amoxicillin and metronidazole) in combination with non-surgical subgingival debridement
Trial: 16403695
Drug: 10-session cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-session cognitive behaviour therapy-based group intervention
Trial: 12808136
Drug: Insulin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (1.5 milliunits/kg of fat‐free mass per min)
Trial: 12808136
Drug: Insulin (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (low to high levels)
Trial: 10702462
Drug: Remifentanil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (50 microg/mL) by syringe from an infusion pump
Trial: 10702462
Drug: Remifentanil 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 20 microg/mL through a minidrip set
Trial: 9112968
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of botulinum toxin type A (BtA)
Trial: 7968331
Drug: 3 mL
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mL 2% lidocaine intrathecally (Group A)
Trial: 7968331
Drug: 15 mL
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mL 2% lidocaine epidurally (Group B)
Trial: 2702851
Drug: bezafibrate (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bezafibrate (600 mg/day)
Trial: 29395407
Drug: Live music
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live music therapy session after wound care in addition to standard care
Trial: 29395407
Drug: Live music
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live music therapy for children older than 5 years
Trial: 9640121
Drug: Propofol target
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol target concentration of 6 micrograms.ml‐1
Trial: 31664751
Drug: 3% TA
RxNorm normalized name: Doak 3% Tar Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% TA combination serum (3% TA, 4% galactomyces ferment filtrate, 2% niacinamide, and 4% alpha arbutin)
Trial: 31664751
Drug: 2% TA
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2% TA combination serum
Trial: 22257645
Drug: DHEA +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA + COC (oral micronized DHEA 50 mg + 20 µg ethinyl estradiol/0.1 mg levonorgestrel combined oral contraceptive pill daily; n = 43)
Trial: 17448045
Drug: GAC brackets
RxNorm normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GAC brackets (G)
Trial: 14752639
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis (ABP)
Trial: 12002922
Drug: Tenoxicam 20
RxNorm normalized name: tenoxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam 20 mg IV
Trial: 15315625
Drug: Tenoxicam 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam 40 mg IV
Trial: 9653594
Drug: Glimepiride plus
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glimepiride plus insulin (GI)
Trial: 9653594
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus insulin (PI)
Trial: 2708607
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment combined with response prevention of vomiting
Trial: 29057266
Drug: Tapered double-lead
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapered double-lead threads single implants placed at the time of tooth extraction (TG)
Trial: 29057266
Drug: Tapered double-lead
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapered double-lead threads single implants placed 3 months after extraction (CG)
Trial: 23378222
Drug: Exposure to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to sexual visual cues ON dopamine medication
Trial: 23378222
Drug: Exposure to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to sexual visual cues OFF dopamine medication
Trial: 19477891
Drug: Clarithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (500 mg daily for 14 days)
Trial: 11440560
Drug: Placebo antitussive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo antitussive syrup (60 ml)
Trial: 6129752
Drug: beta-receptor blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-receptor blockers (talinolol and propranolol)
Trial: 28688338
Drug: Pregnenolone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnenolone (50 mg/day)
Trial: 23217477
Drug: Unilateral spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral spinal anaesthesia (1.5 ml of 0.75% hyperbaric bupivacaine)
Trial: 23217477
Drug: Bilateral spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral spinal anaesthesia (1.5 ml of 0.75% hyperbaric bupivacaine)
Trial: 20382445
Drug: Intravenous 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 0.15 μg/kg sufentanil, followed by 0.075 μg/kg every 3 minutes
Trial: 20382445
Drug: Intravenous 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 0.15 mg/kg morphine, followed by 0.075 mg/kg
Trial: 12709777
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg LY354740
Trial: 12709777
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg LY354740
Trial: 10498345
Drug: 200 IU/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 IU/day of nasal spray of salmon calcitonin
Trial: 1403034
Drug: Aminoglutethimide (AG)
RxNorm normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminoglutethimide (AG) 250 mg four times per day and hydrocortisone 20 mg twice per day
Trial: 4002791
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg muzolimine after a standardized breakfast with 1760 mg aluminium hydroxide administered 10 min before breakfast
Trial: 4002791
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg muzolimine after a standardized breakfast without aluminium hydroxide
Trial: 27852385
Drug: Jinghuaweikang capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jinghuaweikang capsules + furazolidone-based triple therapy (group A1)
Trial: 27852385
Drug: Jinghuaweikang capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jinghuaweikang capsules + furazolidone-based quadruple therapy (group A2)
Trial: 27852385
Drug: Bismuth potassium
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth potassium citrate + furazolidone-based triple therapy (group B1)
Trial: 27852385
Drug: Bismuth potassium
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth potassium citrate + furazolidone-based quadruple therapy (group B2)
Trial: 23173249
Drug: qi supplementing,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: qi supplementing, collateral dredging, detoxifying, and turbidity descending recipe (QSCDDTDR) combined with basic methods of Western medicine (WM)
Trial: 20351374
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment applied at LU6, LI4, ST36 and ST6 for 30 min after exercise
Trial: 20351374
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (rest without acupuncture)
Trial: 7480918
Drug: Oral levamisole
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral levamisole
Trial: 2340610
Drug: Midazolam (0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.07 mg.kg‐1), fentanyl (1 microgram.kg‐1), propofol (2 mg.kg‐1), succinylcholine (1 mg.kg‐1), anaesthesia maintained with propofol (6 mg.kg‐1.hr‐1), N2O (67 per cent), O2 (33 per cent)
Trial: 2340610
Drug: Thiopentone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone (4 mg.kg‐1), anaesthesia maintained with N2O (67 per cent), O2 (33 per cent), enflurane (0.5 per cent inspired concentration)
Trial: 6767648
Drug: Butalamine hydrochloride
RxNorm normalized name: butalamine hydrochloride
DrugBank: Butalamine (DB13681)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butalamine hydrochloride (Adrevil forte) 3 x 2 tablets daily
Trial: 23422925
Drug: Quercetin 500
RxNorm normalized name: quercetin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin 500 mg daily for 13 days
Trial: 23422925
Drug: Quercetin 500
RxNorm normalized name: quercetin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin 500 mg daily for 13 days in MDR1 3435 TT individuals
Trial: 23422925
Drug: Quercetin 500
RxNorm normalized name: quercetin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin 500 mg daily for 13 days in MDR1 3435 CT individuals
Trial: 22027785
Drug: Benazepril 10
RxNorm normalized name: benazepril 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril 10 mg/day
Trial: 15308911
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous morphine infusion (20 mg/day)